# NEUROMARK

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neuromark

- Industry: Medical Devices & Equipment
- Headquarters: Braintree, US
- Website: www.neuromark.com
- Total disclosed funding: $103M
- Latest round: Series C (Feb 11, 2026)
- Investors on record: 10

## About

Based in Ireland, Neurent Medical Ltd. develops innovative treatment solutions for chronic rhinitis, specializing in the NEUROMARK® System that uses radiofrequency technology to alleviate nasal symptoms.Neurent Medical Ltd. is a medical technology company that focuses on chronic rhinitis treatment solutions. Neurent Medical Ltd. is a medical technology company that focuses on chronic rhinitis treatment solutions. Based in Galway, Ireland, Neurent Medical was co-founded by Brian Shields and as of 2026 he is serving as CEO. In February 2026, Neurent Medical Ltd. raised EUR 62.5 million in series C funding led by MVM Partners, with participation from Sofinnova Partners, EQT Life Sciences, Atlantic Bridge, Fountain Healthcare Partners, and Enterprise Ireland. Neurent Medical specializes in the NEUROMARK® System, an advanced device that employs proprietary radiofrequency technology to create lesions that interrupt posterior nasal nerves, alleviating the symptoms of chronic rhinitis. The system is designed for Otolaryngologists, enhancing treatment precision and patient comfort, and is applicable for both newly diagnosed and chronic rhinitis patients. Neurent Medical generates revenue through direct sales of the NEUROMARK® System and related treatment supplies to healthcare institutions and practitioners. The business operates on a B2B model where healthcare providers purchase the system as part of treatment protocols for chronic rhinitis. Revenue is derived from the sale of the device and potential ongoing partnerships for consumable supplies and training services. Neurent Medical plans to utilize the February 2026 funding to to grow sales of NEUROMARK for chronic rhinitis, support clinical studies, and develop new products. The company also intends to explore new markets, focusing on expanding its presence in regions where the demand for chronic rhinitis treatments is growing. Specific details on upcoming product launches and market expansion dates have not been disclosed.

## Funding rounds

- Series C, Feb 11, 2026, $74M — MVM Partners, Sofinnova Partners, EQT Life Sciences, Atlantic Bridge, Fountain Healthcare Partners, Enterprise Ireland
- Series B, Jun 15, 2022, $11M — Atlantic Bridge, Fountain Healthcare Partners, Life Sciences Research Partners, Xenium Capital, Comisión Nacional del Mercado de Valores, Enterprise Ireland
- Series B, Dec 29, 2020, $13M — EQT Life Sciences, Atlantic Bridge, Fountain Healthcare Partners, Western Development Commission, Xenium Capital
- Series A, May 8, 2020, $5.1M — Atlantic Bridge, Fountain Healthcare Partners, Western Development Commission, Enterprise Ireland

## Investors

- Atlantic Bridge (https://capitalatlas.ai/funds/atlantic-bridge) — Series A, Series B, Series C
- Fountain Healthcare Partners (https://capitalatlas.ai/funds/fountain-healthcare-partners) — Series A, Series B, Series C
- Western Development Commission (https://capitalatlas.ai/funds/western-development-commission) — Series A, Series B
- Enterprise Ireland (https://capitalatlas.ai/funds/enterprise-ireland) — Series A, Series B, Series C
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series B, Series C
- Xenium Capital (https://capitalatlas.ai/funds/xenium-capital) — Series B
- Life Sciences Research Partners — Series B
- Comisión Nacional del Mercado de Valores — Series B
- MVM Partners (https://capitalatlas.ai/funds/mvm-partners) — Series C
- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series C